Hanx Bio repurchases 24,900 H shares; treasury holdings rise to 572,200

Bulletin Express05-12

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market buyback of 24,900 H shares on 12 May 2026. The transaction was completed on the Hong Kong Stock Exchange at prices ranging between HKD 31.50 and HKD 32.50, with a volume-weighted average payment of HKD 31.83 per share, bringing the aggregate consideration to HKD 0.79 million.

Following the repurchase, the number of issued shares (excluding treasury shares) fell by 0.018% to 135.65 million. Treasury shares increased from 547,300 to 572,200, while the company’s total issued share count remained unchanged at 136.22 million.

The buyback formed part of the mandate approved on 12 February 2026, which permits the company to repurchase up to 13.62 million shares. Cumulative purchases under this mandate now stand at 572,200 shares, representing 0.42% of the issued share base on the mandate date.

Under Hong Kong listing rules, Hanx Bio is restricted from issuing new shares or disposing of treasury shares until 11 June 2026, 30 days after the latest repurchase.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184038656?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-12 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184038656","market":"us","top_or_hot":-1,"title":"Hanx Bio repurchases 24,900 H shares; treasury holdings rise to 572,200","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market buyback of 24,900 H shares on 12 May 2026. The transaction was completed on the Hong Kong Stock Exchange at prices ranging between HKD 31.50 and HKD 32.50, with a volume-weighted average payment of HKD 31.83 per share, bringing the aggregate consideration to HKD 0.79 million.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) fell by 0.018% to 135.65 million. Treasury shares increased from 547,300 to 572,200, while the company’s total issued share count remained unchanged at 136.22 million.</p>\n<p>The buyback formed part of the mandate approved on 12 February 2026, which permits the company to repurchase up to 13.62 million shares. Cumulative purchases under this mandate now stand at 572,200 shares, representing 0.42% of the issued share base on the mandate date.</p>\n<p>Under Hong Kong listing rules, Hanx Bio is restricted from issuing new shares or disposing of treasury shares until 11 June 2026, 30 days after the latest repurchase.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hanx Bio repurchases 24,900 H shares; treasury holdings rise to 572,200</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHanx Bio repurchases 24,900 H shares; treasury holdings rise to 572,200\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-05-12 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market buyback of 24,900 H shares on 12 May 2026. The transaction was completed on the Hong Kong Stock Exchange at prices ranging between HKD 31.50 and HKD 32.50, with a volume-weighted average payment of HKD 31.83 per share, bringing the aggregate consideration to HKD 0.79 million.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) fell by 0.018% to 135.65 million. Treasury shares increased from 547,300 to 572,200, while the company’s total issued share count remained unchanged at 136.22 million.</p>\n<p>The buyback formed part of the mandate approved on 12 February 2026, which permits the company to repurchase up to 13.62 million shares. Cumulative purchases under this mandate now stand at 572,200 shares, representing 0.42% of the issued share base on the mandate date.</p>\n<p>Under Hong Kong listing rules, Hanx Bio is restricted from issuing new shares or disposing of treasury shares until 11 June 2026, 30 days after the latest repurchase.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1184038656","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184038656","pubTimestamp":1778586220,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market buyback of 24,900 H shares on 12 May 2026. The transaction was completed on the Hong Kong Stock Exchange at prices ranging between HKD...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉克斯生物回购2.49万股H股；国债持有量升至572,200","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. executed an on-market buyback of 24,900 H shares on 12 May 2026. The transaction was completed on the Hong Kong Stock Exchange at prices ranging between HKD 31.50 and HKD 32.50, with a volume-weighted average payment of HKD 31.83 per share, bringing the aggregate consideration to HKD 0.79 million.\nFollowing the repurchase, the number of issued shares (excluding treasury shares) fell by 0.018% to 135.65 million. Treasury shares increased from 547,300 to 572,200, while the company’s total issued share count remained unchanged at 136.22 million.\nThe buyback formed part of the mandate approved on 12 February 2026, which permits the company to repurchase up to 13.62 million shares. Cumulative purchases under this mandate now stand at 572,200 shares, representing 0.42% of the issued share base on the mandate date.\nUnder Hong Kong listing rules, Hanx Bio is restricted from issuing new shares or disposing of treasury shares until 11 June 2026, 30 days after the latest repurchase.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184038656","isCrawlerRequest":true}